In Brief This Week: PerkinElmer, Danaher; Venaxis; Nuclea Biotechnologies; AdvanDx; Covaris | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank ISI Group this week downgraded shares of PerkinElmer and upgraded shares of Danaher.

In a research note, analyst Ross Muken lowered the rating for PerkinElmer to Neutral from Buy, saying that the company's stock is "now approaching the upper end of its historical range, and therefore we see limited opportunity for multiple expansion." He maintained a $49 price target on PerkinElmer's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.